Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

91.03 -8.01 (-8.08%)

Streaming Delayed Price Updated: 3:42 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Spotlight on Insmed: Analyzing the Surge in Options Activity ↗

September 25, 2025

Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ: INSM) revealed 29 unusual trades.

Via Benzinga

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

September 22, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

Deep Dive Into Insmed Stock: Analyst Perspectives (26 Ratings) ↗

September 03, 2025

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease ↗

August 12, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

What Does the Market Think About Insmed? ↗

June 19, 2025

Via Benzinga

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It ↗

September 02, 2025

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Via Investor's Business Daily

Israel Englander's Millennium Goes All-In On Crypto And Healthcare While Rebalancing Big Tech Bets: Bitcoin ETF And Palantir Stakes Soar In Q2 ↗

August 27, 2025

Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalancing. Read key changes!

Via Benzinga

Topics ETFs

Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind ↗

August 26, 2025

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Via Stocktwits

Topics Earnings

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗

August 21, 2025

Via Benzinga

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 21, 2025

Via Benzinga

Lung Disease-Focused Insmed 'Must-Own' Name For Investors ↗

August 20, 2025

Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035

Via Benzinga

Intel, UnitedHealth, And Reddit Are Among Top Large Cap Gainers Last Week (August 11-August 15): Are The Others In Your Portfolio? ↗

August 17, 2025

These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 14, 2025

Via Benzinga

Assessing Insmed: Insights From 20 Financial Analysts ↗

August 13, 2025

Via Benzinga

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗

August 13, 2025

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Via Stocktwits

Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

August 13, 2025

Via Benzinga

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic ↗

August 13, 2025

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

Via Stocktwits

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease ↗

August 12, 2025

The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients.

Via Benzinga

Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval ↗

August 12, 2025

Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition.

Via Investor's Business Daily

$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗

August 07, 2025

Via Benzinga

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

Via Investor Brand Network

Topics Government

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗

July 24, 2025

Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.

Via Investor's Business Daily

Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' ↗

July 10, 2025

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for...

Via Benzinga

Topics Artificial Intelligence

A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts ↗

July 08, 2025

Via Benzinga

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

July 02, 2025

Via Benzinga

Russell Rebalance: 3 Stocks Ready to Move Higher

June 20, 2025

The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.